Abstract
Beta-blocker therapy is critical in the management of coronary artery disease. Although its role is better defined in the management of acute myocardial infarction with areas of lingering controversy, β-blocker use in terms of cardiovascular outcomes in stable coronary artery disease is less understood. In this heterogenous population, important questions arise about what groups of patients benefit most from β-blockers and the appropriate duration of use.
| Original language | English (US) |
|---|---|
| Title of host publication | Beta-Blockers |
| Subtitle of host publication | Physiological, Pharmacological and Therapeutic Implications |
| Publisher | Nova Science Publishers, Inc. |
| Pages | 287-298 |
| Number of pages | 12 |
| ISBN (Electronic) | 9781536133127 |
| ISBN (Print) | 9781536133110 |
| State | Published - Jan 1 2018 |
ASJC Scopus subject areas
- Medicine(all)
- Pharmacology, Toxicology and Pharmaceutics(all)
Fingerprint Dive into the research topics of 'Beta-Blocker therapy for acute coronary syndrome and stable coronary artery disease: Current issues and outcomes'. Together they form a unique fingerprint.
Cite this
Kesarwani, M. (2018). Beta-Blocker therapy for acute coronary syndrome and stable coronary artery disease: Current issues and outcomes. In Beta-Blockers: Physiological, Pharmacological and Therapeutic Implications (pp. 287-298). Nova Science Publishers, Inc..